Brief: Sesen Bio Reports Fourth Quarter 2021 Results And Anticipated Path Forward For Lead Candidate, Vicineum

Carisma Therapeutics

28/02/2022 14:30

Feb 28 (Reuters) - Sesen Bio Inc  SESN.O :
    * SESEN BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2021
FINANCIAL
RESULTS AND ANTICIPATED REGULATORY PATH FORWARD FOR THE
COMPANY’S LEAD PRODUCT CANDIDATE, VICINEUM™
    * SESEN BIO INC - $163M IN CASH AND CASH EQUIVALENTS AS OF
DECEMBER 31, 2021 EXPECTED TO FUND CURRENT OPERATING PLAN INTO
2024
    * SESEN BIO INC QTRLY EARNINGS PER SHARE $0.04

Source text for Eikon:  ID:nBw2sBxMqa 
Further company coverage:  SESN.O 

 ((Reuters.Briefs@thomsonreuters.com;))